According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Educational information

The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.

These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.

This recording was developed under auspices of PACE-cme.

The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Faculty

Prof. Ulf Landmesser, MD - Charité-Universitätsmedizin Berlin, Berlin, Germany

Disclosures

Funding to produce this expert opinion was provided by an unrestricted educational grant from Novartis.

Klicken Sie hier, um die Deutsche Version anzuzeigen See more Inflammation Expert Opinions